-
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who understand them and what...
IN THE SPOTLIGHT
-
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their... -
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung... -
Initial Treatment Options for HER2+ NSCLC Expand with New Zongertinib Approval
On February 26, 2026, the US Food and Drug Administration (FDA) announced the accelerated approval of zongertinib (Hernexeos®) as an initial treatment option for newly diagnosed... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
New Accelerated Approval for HER2-positive NSCLC
On November 19, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of sevabertinib (Hyrnuo®) to treat patients with locally-advanced or metastatic... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community...
Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC
Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC
XGBoost and SHAP based lymph node ratio thresholds for predicting overall survival in stage I to IIIA NSCLC
XGBoost and SHAP based lymph node ratio thresholds for predicting overall survival in stage I to IIIA NSCLC
Integrative Transcriptomic Analysis Identifies COL3A1 as a Potential Tumor-Intrinsic Therapeutic Target in NSCLC
Integrative Transcriptomic Analysis Identifies COL3A1 as a Potential Tumor-Intrinsic Therapeutic Target in NSCLC
NICE Recommends Combination Treatment For Advanced NSCLC
Daniela Miliziano: Great Experience At AACR Presenting Our RET-MAP Registry Work In RET+ NSCLC
Daniela Miliziano: Great Experience At AACR Presenting Our RET-MAP Registry Work In RET+ NSCLC
First-Line Zongertinib in Advanced HER2-Mutant NSCLC
Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO
Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO
South Korea approves Bayer’s Hernuo to treat HER2-mutant NSCLC
EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors; First-in-human study of EPI-326 will evaluate the company's...
EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors; First-in-human study of EPI-326 will evaluate the company's...